Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Filings indexed 1,237 across all filing types
Latest filing 2024-11-07 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Pursuant to the provisions of Regulation 30 read with sub-para 20, Part A, Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby submit ....
Regulatory Filings Classification · 95% confidence The document is a disclosure made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It reports an audit observation letter imposing GST liability with interest and penalty against the company. The document is addressed to stock exchanges and provides details of the audit observation and financial impact. It is a regulatory announcement about a legal/tax matter rather than a full audit report or annual report. The document length is short (2937 characters) and it serves as a formal disclosure of a regulatory/legal issue. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like Audit Report or Legal Proceedings Report.
2024-11-07 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Narsimha Shibroor Kamath & PACs
Regulatory Filings
2024-10-30 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Narsimha Shibroor Kamath & PACs
Regulatory Filings
2024-10-30 English
Copy of Newspaper Publication
Regulatory Filings
2024-10-28 English
Enclosed herewith the copies of the newspaper advertisement published regarding the extract of the statement of unaudited standalone and consolidated financial results for the quarter and ....
Regulatory Filings
2024-10-28 English
Outcome of Board Meeting
Regulatory Filings
2024-10-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.